Mild Cognitive Impairment Clinical Trial
Official title:
Effects of Mild Cognitive Impairment on Auditory System and Its Correlation With Cognitive Function: a Multicenter, Randomized Controlled Study
NCT number | NCT05336942 |
Other study ID # | PKJ2019-Y24 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 1, 2020 |
Est. completion date | March 30, 2022 |
Verified date | April 2022 |
Source | Tongji University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Cognitive dysfunction is a high incidence disease in the elderly. To date, there is no effective treatment. At the same time, early cognitive impairment is easy to be ignored, delayed intervention. Most patients develop moderate or severe dementia with hearing loss before treatment. At present, there are few studies on the correlation between mild cognitive impairment and hearing function. The investigators evaluated CDR, MMSE, MoCa, and hearing tests at baseline, 6 months later, and 12 months later in a multicenter, randomized cohort study of adults aged 55-65 years. To investigate the correlation between mild cognitive impairment and hearing impairment and its possible predictors. The investigators hope to provide more evidence-based evidence for early identification of mild cognitive impairment.
Status | Completed |
Enrollment | 90 |
Est. completion date | March 30, 2022 |
Est. primary completion date | December 30, 2021 |
Accepts healthy volunteers | |
Gender | All |
Age group | 55 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. The registered residence of local residents is more than one month. 2. Aged 55 to 65 years. 3. Be able to conduct verbal communication or written conversation, or complete the investigation with the help of family members. Exclusion Criteria: 1. Mini-mental state examination(MMSE), illiterate group = 17 points, primary school group = 20 points, middle school or above group 24 points; 2. Those who meet the ICD-10 diagnostic criteria for dementia; 3. Those who are obviously blind or have difficulty in speech expression; 4. Persons suffering from serious physical diseases; 5. Those who meet the diagnostic criteria of schizophrenia, neurosis, organic mental disorder and mental retardation; 6. Persons with severe or above hearing impairment; 7. Those who are unable to sign the informed consent form. |
Country | Name | City | State |
---|---|---|---|
China | Tongji University | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Tongji University |
China,
Heywood R, Gao Q, Nyunt MSZ, Feng L, Chong MS, Lim WS, Yap P, Lee TS, Yap KB, Wee SL, Ng TP. Hearing Loss and Risk of Mild Cognitive Impairment and Dementia: Findings from the Singapore Longitudinal Ageing Study. Dement Geriatr Cogn Disord. 2017;43(5-6):2 — View Citation
Jongsiriyanyong S, Limpawattana P. Mild Cognitive Impairment in Clinical Practice: A Review Article. Am J Alzheimers Dis Other Demen. 2018 Dec;33(8):500-507. doi: 10.1177/1533317518791401. Epub 2018 Aug 1. Review. — View Citation
Khan HZ, Park CY, Lim MA, Beltran AJ, Farquhar D, Yencha M, Capra GG. Radiographic findings in young adults with asymmetric sensorineural hearing loss. Am J Otolaryngol. 2019 Jan - Feb;40(1):78-82. doi: 10.1016/j.amjoto.2018.10.003. Epub 2018 Oct 11. — View Citation
Lin FR, Yaffe K, Xia J, Xue QL, Harris TB, Purchase-Helzner E, Satterfield S, Ayonayon HN, Ferrucci L, Simonsick EM; Health ABC Study Group. Hearing loss and cognitive decline in older adults. JAMA Intern Med. 2013 Feb 25;173(4):293-9. doi: 10.1001/jamain — View Citation
Maharani A, Pendleton N, Leroi I. Hearing Impairment, Loneliness, Social Isolation, and Cognitive Function: Longitudinal Analysis Using English Longitudinal Study on Ageing. Am J Geriatr Psychiatry. 2019 Dec;27(12):1348-1356. doi: 10.1016/j.jagp.2019.07.0 — View Citation
Ringman JM, Medina LD, Rodriguez-Agudelo Y, Chavez M, Lu P, Cummings JL. Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. Curr Alzheimer Res. 2009 Aug;6(4):341-6. — View Citation
Srikanth V, Sinclair AJ, Hill-Briggs F, Moran C, Biessels GJ. Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. Lancet Diabetes Endocrinol. 2020 Jun;8(6):535-545. doi: 10.1016/S2213-8587(20)30118-2. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mini-mental state examination (MMSE) | To screen and assess the extent of cognitive dysfunction. | Baseline | |
Primary | Mini-mental state examination (MMSE) | To screen and assess the extent of cognitive dysfunction. | 6-month | |
Primary | Mini-mental state examination (MMSE) | To screen and assess the extent of cognitive dysfunction. | 12-month | |
Primary | Montreal Cognitive Assessment (MocA) | To evaluate various domains of cognition. | Baseline | |
Primary | Montreal Cognitive Assessment (MocA) | To evaluate various domains of cognition. | 6-month | |
Primary | Montreal Cognitive Assessment (MocA) | To evaluate various domains of cognition. | 12-month | |
Primary | Pure tone Listening Test (PTA) | To determine the threshold intensity of hearing at each frequency and measure the nature and extent of hearing loss. | Baseline | |
Primary | Pure tone Listening Test (PTA) | To determine the threshold intensity of hearing at each frequency and measure the nature and extent of hearing loss. | 6-month | |
Primary | Pure tone Listening Test (PTA) | To determine the threshold intensity of hearing at each frequency and measure the nature and extent of hearing loss. | 12-month | |
Secondary | Clinical Dementia Rating (CDR) | To generated to stage the severity of dementia. | Baseline | |
Secondary | Clinical Dementia Rating (CDR) | To generated to stage the severity of dementia. | 6-month | |
Secondary | Clinical Dementia Rating (CDR) | To generated to stage the severity of dementia. | 12-month | |
Secondary | Auditory brainstem response (ABR) | To evaluate objectively the hearing level by the response threshold of V wave. | Baseline | |
Secondary | Auditory brainstem response (ABR) | To evaluate objectively the hearing level by the response threshold of V wave. | 6-month | |
Secondary | Auditory brainstem response (ABR) | To evaluate objectively the hearing level by the response threshold of V wave. | 12-month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |